[go: up one dir, main page]

HK1098356A1 - 用於哮喘和copd长期治疗的抗胆硷能药和糖皮质激素的组合 - Google Patents

用於哮喘和copd长期治疗的抗胆硷能药和糖皮质激素的组合 Download PDF

Info

Publication number
HK1098356A1
HK1098356A1 HK07104757.8A HK07104757A HK1098356A1 HK 1098356 A1 HK1098356 A1 HK 1098356A1 HK 07104757 A HK07104757 A HK 07104757A HK 1098356 A1 HK1098356 A1 HK 1098356A1
Authority
HK
Hong Kong
Prior art keywords
glycopyrrolate
asthma
copd
acceptable salt
pharmaceutical composition
Prior art date
Application number
HK07104757.8A
Other languages
English (en)
Chinese (zh)
Other versions
HK1098356B (en
Inventor
J.格德
J.毛斯
P.J.克诺塔
I.塞莱尼
Original Assignee
Meda制药有限及两合公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda制药有限及两合公司 filed Critical Meda制药有限及两合公司
Publication of HK1098356A1 publication Critical patent/HK1098356A1/xx
Publication of HK1098356B publication Critical patent/HK1098356B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK07104757.8A 2004-02-06 2005-01-24 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd HK1098356B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54195604P 2004-02-06 2004-02-06
US60/541,956 2004-02-06
PCT/EP2005/000652 WO2005074918A1 (en) 2004-02-06 2005-01-24 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd

Publications (2)

Publication Number Publication Date
HK1098356A1 true HK1098356A1 (zh) 2007-07-20
HK1098356B HK1098356B (en) 2010-08-13

Family

ID=

Also Published As

Publication number Publication date
ES2413011T3 (es) 2013-07-15
WO2005074918A1 (en) 2005-08-18
DK1713473T3 (da) 2013-06-17
CA2551780C (en) 2013-02-26
AU2005210085B2 (en) 2010-06-24
CN1913883A (zh) 2007-02-14
NZ548300A (en) 2010-04-30
NO336882B1 (no) 2015-11-23
JP4819699B2 (ja) 2011-11-24
AU2005210085A1 (en) 2005-08-18
RU2006132038A (ru) 2008-03-20
NO20063879L (no) 2006-11-01
US20080300226A1 (en) 2008-12-04
EP1713473A1 (en) 2006-10-25
RU2440813C2 (ru) 2012-01-27
EP1713473B1 (en) 2013-03-13
PL1713473T3 (pl) 2013-08-30
PT1713473E (pt) 2013-05-13
JP2007520508A (ja) 2007-07-26
CA2551780A1 (en) 2005-08-18
CN100569235C (zh) 2009-12-16
US10537550B2 (en) 2020-01-21
US20050175548A1 (en) 2005-08-11
SI1713473T1 (sl) 2013-06-28
HRP20130460T1 (hr) 2013-06-30

Similar Documents

Publication Publication Date Title
US10537550B2 (en) Methods of treating underlying inflammation from COPD or asthma
JP2020023537A (ja) Copdの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ
EP2207538A1 (en) Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti -inflammatory and the use thereof for the treatment of respiratory disorders
US20140329782A1 (en) Combined therapeutic agent
Hsieh et al. Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients
US20220218672A1 (en) Thromboxane Receptor Antagonists in AERD/Asthma
KR20180119597A (ko) 염증 상태의 급성 악화의 치료를 위한 투약법
AU2003292120B2 (en) New synergistic combination comprising roflumilast and formoterol
HK1098356B (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
MXPA06008938A (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
JP5220741B2 (ja) アンドラスト/グルココルチコイドの併用
Yerbury et al. 3 Symptom Management
Connolly Drugs and the Lung—COPD, Asthma, Interstitial Lung Disease
JP2013056925A (ja) アンドラスト/グルココルチコイドの併用
HK1232788A1 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd
HK1087009A1 (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
HK1087009B (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220126